Levetiracetam is not effective for essential tremor.

Abstract:

OBJECTIVE:To determine if levetiracetam is efficacious in the treatment of essential tremor. METHODS:Fifteen patients (3 women), aged 35 to 83 years, with essential tremor were studied in a double-blind, placebo-controlled crossover trial of levetiracetam. During the 2 treatment periods, levetiracetam or placebo was titrated from 500 to 3000 mg/d during a 5-week titration phase, as tolerated, and the maximum tolerated dosage was then maintained for 4 weeks. There was a 3-week washout phase between the 2 treatment periods. Patients were assessed with the Fahn-Tolosa-Marín tremor rating scale (TRS), and tremor in the spiral and line drawings of 7 patients was quantified with a computerized digitizing tablet. Changes in other antitremor medications (10 patients) were not permitted during the study. RESULTS:The planned enrollment of 45 patients was stopped when an interim analysis of the first 15 patients revealed no efficacy. One patient failed to achieve the 3000-mg/d dosage of levetiracetam. Three patients dropped out of the study due to lack of efficacy and other side effects. The analysis of TRS data with these three patients excluded and after imputing their missing data (last value carried forward) revealed a statistically insignificant trend for all TRS and tablet measures to be worse when patients were taking levetiracetam. There was no period effect or treatment-period interaction for any measure of tremor. The results were the same for the 5 patients taking no other antitremor medications. CONCLUSIONS:Levetiracetam is not beneficial in the treatment of essential tremor.

journal_name

Clin Neuropharmacol

authors

Elble RJ,Lyons KE,Pahwa R

doi

10.1097/WNF.0b013E31807A32C6

subject

Has Abstract

pub_date

2007-11-01 00:00:00

pages

350-6

issue

6

eissn

0362-5664

issn

1537-162X

pii

00002826-200711000-00005

journal_volume

30

pub_type

临床试验,杂志文章,多中心研究,随机对照试验
  • Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease.

    abstract::We investigated genetic polymorphism of the cytochrome P-450 CYP2D6 gene from white patients with idiopathic Parkinson's disease (IPD). The mutations of the CYP2D6 gene associated with the poor metabolizer (PM) phenotype of the debrisoquine/sparteine polymorphism were analyzed in DNA of 130 IPD patients by a polymeras...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199619030-00003

    authors: Bordet R,Broly F,Destée A,Libersa C,Lafitte JJ

    更新日期:1996-06-01 00:00:00

  • Poor tolerability of a transdermal nicotine treatment in Parkinson's disease.

    abstract::Studies assessing the effect of transdermal nicotine in Parkinson's disease (PD) have generated mixed results regarding its efficacy to treat motor and cognitive deficits. These studies generally reported good tolerability in nonsmoking PD patients. The authors report the tolerability data of an open trial with transd...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200309000-00004

    authors: Lemay S,Blanchet P,Chouinard S,Masson H,Soland V,Bédard MA

    更新日期:2003-09-01 00:00:00

  • A study of salivary secretion in Parkinson's disease.

    abstract::Hypersialorrhea is frequently reported in patients with idiopathic Parkinson's Disease (PD). Excessive production of saliva, swallowing difficulties, or both could explain this complaint. Dopamine (DA) has been shown to modulate salivary secretion in a number of vertebrate and invertebrate species. The present study w...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Bagheri H,Damase-Michel C,Lapeyre-Mestre M,Cismondo S,O'Connell D,Senard JM,Rascol O,Montastruc JL

    更新日期:1999-07-01 00:00:00

  • Therapeutic effects of arotinolol, a beta-adrenergic blocker, on tremor in MPTP-induced parkinsonian monkeys.

    abstract::The effect of arotinolol, a peripherally acting beta-adrenergic-blocking agent, on postural or kinetic tremor was studied in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Male cynomolgus monkeys (Macaca fascicularis) were treated with three injections of MPTP hydrochloride (0.3...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199210000-00005

    authors: Kuno S,Mizuta E,Nishida J,Takechi M

    更新日期:1992-10-01 00:00:00

  • Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials.

    abstract::The extensive use of the Unified Parkinson's Disease Rating Scale (UPDRS) has revealed low interrater reliability in some items and redundancy in others. In view of these shortcomings, we have structured a new scale that includes a zero-to three-point scale for each item in the evaluation of PD. The mental axis includ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rabey JM,Bass H,Bonuccelli U,Brooks D,Klotz P,Korczyn AD,Kraus P,Martinez-Martin P,Morrish P,Van Sauten W,Van Hilten B

    更新日期:1997-08-01 00:00:00

  • Reboxetine addition in patients with mirtazapine-resistant depression: a case series.

    abstract:OBJECTIVES:Treatment-resistant depression is a common occurrence in clinical practice as well as combination treatment with 2 different antidepressants. In the present case series, we study the effectiveness of the addition of reboxetine, during 12 weeks, to 14 outpatients diagnosed with major depressive disorder, acco...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/01.WNF.0000228211.19818.14

    authors: López-Muñoz F,Rubio G,Alamo C,García-García P,Pardo A

    更新日期:2006-07-01 00:00:00

  • Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.

    abstract::A matter of debate is the impact of levodopa (LD) application in patients with Parkinson disease (PD) on altered force development and coordination, which are also influenced by the strength of muscles used. The objectives were to compare the motor response, the development of grip strength, and the pharmacokinetic be...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31811510ed

    authors: Müller T,Kolf K,Ander L,Woitalla D,Muhlack S

    更新日期:2008-05-01 00:00:00

  • A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.

    abstract::Botulinum toxin A (BTA) is considered an effective treatment of cervical dystonia. The aim of this prospective, randomized, double-blind study was to compare Botox and Prosigne, a BTA of Chinese origin, with a view to establish the safety, the efficacy, and the equivalence of doses of the 2 formulations in the treatme...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/WNF.0b013e3181c46f48

    authors: Quagliato EM,Carelli EF,Viana MA

    更新日期:2010-01-01 00:00:00

  • Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease.

    abstract::We studied the effectiveness of OR-611 and OR-462, two novel inhibitors of the enzyme catechol-O-methyltransferase (COMT), on 3-O-methyldopa (OMD) formation in cynomolgus monkeys following intravenous levodopa administration. OR-611 dose-dependently reduced the area under the OMD concentration-vs-time curve, reduced m...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199108000-00005

    authors: Cedarbaum JM,Leger G,Guttman M

    更新日期:1991-08-01 00:00:00

  • No effect of chronic bromocriptine therapy on levodopa pharmacokinetics in patients with Parkinson's disease.

    abstract::We studied the effect of chronic bromocriptine cotherapy on levodopa kinetics in seven patients with Parkinson's disease who were receiving levodopa therapy. Plasma levodopa concentrations were measured after a standard oral levodopa fasting dose over a 5-hour period, on two different sessions, without and with bromoc...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199212000-00008

    authors: Contin M,Riva R,Martinelli P,Albani F,Baruzzi A

    更新日期:1992-12-01 00:00:00

  • Relief of intractable posthypoxic myoclonus after administration of agomelatine.

    abstract::Chronic posthypoxic myoclonus is characterized by myoclonic jerks that are specifically triggered by action. It is a rare but devastating sequela of hypoxic encephalopathy. We report a 42-year-old female patient with treatment-resistant chronic posthypoxic myoclonus, which improved with administration of the drug agom...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e3182613e06

    authors: González de la Aleja J,Saiz-Díaz RA,De la Peña P

    更新日期:2012-09-01 00:00:00

  • Memory deficits of aged male rats can be improved by pyrimidine nucleosides and n-acetyl-glutamine.

    abstract::The pyrimidine nucleosides uridine (URI) and cytidine (CYT), alone or associated with n-acetyl-glutamine (NAG), were injected acutely or subchronically to aged (26 months old) male rats of the Sprague-Dawley strain. Learning and memory abilities of the animals were studied with tests of avoidance behavior. The acquisi...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199008000-00002

    authors: Drago F,D'Agata V,Valerio C,Spadaro F,Raffaele R,Nardo L,Grassi M,Freni V

    更新日期:1990-08-01 00:00:00

  • A Pilot Study of Randomized, Head-to-Head of Metformin Versus Topiramate in Obese People With Schizophrenia.

    abstract:OBJECTIVES:A number of research studies support the weight loss effects of metformin and topiramate for obese people with schizophrenia. However, only a few studies have addressed the sustainability of the body weight reduction after discontinuation of these drugs. Moreover, head-to-head studies are still lacking. The ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0000000000000188

    authors: Peng PJ,Ho PS,Tsai CK,Huang SY,Liang CS

    更新日期:2016-11-01 00:00:00

  • A review of the antiepileptic drug tiagabine.

    abstract::Tiagabine (TGB), a recently approved antiepileptic drug (AED), has a specific mechanism of action that is unique among AEDs. A potent AED with linear, predictable pharmacokineties, it inhibits gamma-aminobutyric acid (GABA) reuptake into neurons and glia. Tiagabine does not have any clinically relevant effects on hepa...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Schachter SC

    更新日期:1999-11-01 00:00:00

  • Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.

    abstract:OBJECTIVES:Ponezumab is a humanized antiamyloid beta (Aβ) monoclonal antibody designed to treat Alzheimer disease (AD). METHODS:This randomized, double-blind, single-dose-escalation study evaluated the safety, pharmacokinetics, and pharmacodynamics of 0.1, 0.3, 1, 3, and 10 mg/kg ponezumab (n = 4, 4, 4, 6, and 8, resp...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/WNF.0b013e31827db49b

    authors: Landen JW,Zhao Q,Cohen S,Borrie M,Woodward M,Billing CB Jr,Bales K,Alvey C,McCush F,Yang J,Kupiec JW,Bednar MM

    更新日期:2013-01-01 00:00:00

  • Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia.

    abstract:BACKGROUND AND PURPOSE:Treatment of chronic insomnia with nightly hypnotics is efficacious, but discontinuation is recommended after 1 month, less than the average disease duration. This study was undertaken to determine the efficacy of intermittent administration. PATIENTS AND METHODS:A double-blind study was carried...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/wnf.0b013e3180674e0e

    authors: Parrino L,Smerieri A,Giglia F,Milioli G,De Paolis F,Terzano MG

    更新日期:2008-01-01 00:00:00

  • Paroxetine-associated hypereosinophilia may clinically resemble a panic attack.

    abstract::Hypereosinophilia is asymptomatic but can induce organ damage, which may cause neurological system abnormalities. We recently encountered a 29-year-old woman with depressive episodes who had eosinophilia as well as hyperventilation attacks, tremor, insomnia, and arthralgia of extremities after receiving paroxetine tre...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31823da9a8

    authors: Yasui-Furukori N,Sato Y,Kato H,Kaneko S

    更新日期:2012-01-01 00:00:00

  • Adjunctive use of methylphenidate in the treatment of psychotic unipolar depression.

    abstract::Adjunctive use of methylphenidate, a central stimulant, has been considered as a potential therapeutic choice for patients with refractory unipolar depression, geriatric depression, bipolar depression, and depression secondary to a medical illness. We present a case of psychotic unipolar depression in which the patien...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e318157d998

    authors: Huang CC,Shiah IS,Chen HK,Mao WC,Yeh YW

    更新日期:2008-07-01 00:00:00

  • Knee Buckling (Negative Myoclonus) Associated With Clozapine: Reports on 3 Cases.

    abstract:BACKGROUND:Negative myoclonus is rarely seen in the clinical setting. It can be involved in some central nervous system pathologies. It has also been observed after antipsychotic treatment. CASE REPORTS:In this article, we will present 3 cases diagnosed with negative myoclonus in a 120-bed university-affiliated hospit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000370

    authors: Uzun Ö,Bolu A,Taşçi AB,Oğur B

    更新日期:2020-01-01 00:00:00

  • Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.

    abstract:OBJECTIVES:Aripiprazole and ziprasidone are 2 antipsychotic medications that are relatively devoid of the metabolic adverse effects associated with the second-generation antipsychotics. This study aimed to evaluate the effectiveness of switching to ziprasidone in patients who had insufficient response or intolerance to...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/WNF.0b013e3181d52b85

    authors: Kim SW,Shin IS,Kim JM,Bae KY,Yang SJ,Yoon JS

    更新日期:2010-05-01 00:00:00

  • Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study.

    abstract:BACKGROUND:Introduction of old and new generations of antipsychotics leads to significant improvements in the positive symptoms of schizophrenia. However, negative symptoms remain refractory to conventional trials of antipsychotic therapy. Recently, there were several open clinical human trials with curcumin. Curcumin ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0000000000000344

    authors: Miodownik C,Lerner V,Kudkaeva N,Lerner PP,Pashinian A,Bersudsky Y,Eliyahu R,Kreinin A,Bergman J

    更新日期:2019-07-01 00:00:00

  • The changes of cortical metabolism associated with the clinical response to donepezil therapy in traumatic brain injury.

    abstract:OBJECTIVES:To determine the effects of treatment with donepezil on cortical metabolism in patients with traumatic brain injury using F-fluorodeoxyglucose positron emission tomography. METHODS:Twenty-six patients with cognitive impairment after traumatic brain injury were enrolled and randomly assigned into the donepez...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0B013E31816F1BC1

    authors: Kim YW,Kim DY,Shin JC,Park CI,Lee JD

    更新日期:2009-03-01 00:00:00

  • Investigating the efficacy of paroxetine in developmental stuttering.

    abstract:OBJECTIVES:Paroxetine has been reported to be useful for management of stuttering symptoms, but only a few reports have examined its effects. We have investigated the efficacy of paroxetine in a randomized, placebo-controlled study. METHODS:Five stuttering subjects received paroxetine at 20 mg once daily at night for ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0b013e31819817eb

    authors: Busan P,Battaglini PP,Borelli M,Evaristo P,Monti F,Pelamatti G

    更新日期:2009-07-01 00:00:00

  • Levodopa efficacy and pathological basis of Parkinson syndrome.

    abstract::Levodopa is the most effective drug for symptomatic control of Parkinson syndrome (PS). We report a 22-year clinicopathological study of 59 PS cases. Of the entire group, 37 (63%) had an adequate trial on levodopa. Some improvement was noted on that drug in 24 (65%) cases. Improvement was seen in 94% of idiopathic Par...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199012000-00007

    authors: Rajput AH,Rozdilsky B,Rajput A,Ang L

    更新日期:1990-12-01 00:00:00

  • Severe weight gain induced by combination treatment with risperidone and paroxetine.

    abstract::Successful combination therapy with atypical antipsychotics and selective serotonin reuptake inhibitors has been reported for several psychiatric conditions. However, great attention should be paid to the possible adverse effects. In this retrospective chart review, we focused on the drug-drug interaction of paroxetin...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200209000-00009

    authors: Fukui H,Murai T

    更新日期:2002-09-01 00:00:00

  • Memantine Rescues Neurosyphilis-Related Schizophrenic-like Features and Cognitive Deficit.

    abstract:OBJECTIVES:Neurosyphilis, an infectious neuroinflammatory disorder, could cause diverse neuropsychiatric symptoms mimicking disorders of schizophrenia and dementia; hence, it is known as the "chameleon of psychiatry." Here, we present a subject with neurosyphilis with schizophrenic features and share the treatment outc...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000347

    authors: Chen WC,Wang HY,Chen PA,Chen IC,Chen YC

    更新日期:2019-07-01 00:00:00

  • Dopamine dysregulation syndrome and levodopa-induced dyskinesias in Parkinson disease: common consequences of anomalous forms of neural plasticity.

    abstract::Four to 10% of patients with Parkinson disease and chronically treated with levodopa undergo an addictionlike behavioral disturbance named dopamine dysregulation syndrome (DDS). This article suggests that patients with Parkinson disease could be especially prone to develop DDS due to the dopamine deficiency and the "p...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0B013E3181634EA6

    authors: Linazasoro G

    更新日期:2009-01-01 00:00:00

  • Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.

    abstract::Fifty-six chronic schizophrenic patients were randomized into haloperidol decanoate (HD) or placebo groups for 48 weeks of double-blind treatment. The double-blind trial was preceded by a 15-week single-blind run-in period, during which all patients were treated with 60 mg of HD (approximately corresponding to 3.6 mg ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Eklund K,Forsman A

    更新日期:1991-01-01 00:00:00

  • A new clinical tool for gait evaluation in Parkinson's disease.

    abstract::This study was devised to check the feasibility and validity of a rating scale specifically designed to evaluate gait impairment in Parkinson's disease (RSGE). Demographic data, a brief questionnaire on general aspects influencing gait and mobility, a battery of scales (Barthel Index; Hoehn and Yahr staging; and North...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/00002826-199706000-00001

    authors: Martínez-Martín P,García Urra D,del Ser Quijano T,Balseiro Gómez J,Gómez Utrero E,Piñeiro R,Andrés MT

    更新日期:1997-06-01 00:00:00

  • Cytosolic and nuclear sex steroid receptors in meningioma.

    abstract::To determine the nature of the hormone dependency of meningioma, particularly whether progestin receptor (PR) and tumor growth are estrogen-dependent, we measured the cytosol estrogen receptor (ER) and PR separately by an exchange assay with [3H]R 2858 (for ER) and [3H]RU 27987 (for PR) in 21 meningiomas. We correlate...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198412000-00018

    authors: Moguilewsky M,Pertuiset BF,Verzat C,Philibert D,Philippon J,Poisson M

    更新日期:1984-01-01 00:00:00